Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics

See allHide authors and affiliations

Science Advances  17 Apr 2019:
Vol. 5, no. 4, eaaw1567
DOI: 10.1126/sciadv.aaw1567

Article Information

vol. 5 no. 4

Online ISSN: 
  • Received for publication November 22, 2018
  • Accepted for publication March 5, 2019
  • .

Author Information

  1. Mikail Weston1,*,
  2. Teresa Kaserer2,*,
  3. Angela Wu3,
  4. Alexandre Mouravlev3,
  5. Jenna C. Carpenter1,
  6. Albert Snowball1,
  7. Samuel Knauss1,,
  8. Melanie von Schimmelmann4,
  9. Matthew J. During4,
  10. Gabriele Lignani1,
  11. Stephanie Schorge1,,
  12. Deborah Young3,
  13. Dimitri M. Kullmann1,§ and
  14. Andreas Lieb1,§
  1. 1Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, University College London, London, UK.
  2. 2Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.
  3. 3Department of Pharmacology & Clinical Pharmacology, The University of Auckland, Auckland, New Zealand.
  4. 4Ovid Therapeutics, Inc., 1460 Broadway, New York, NY 10036, USA.
  1. §Corresponding author. Email: d.kullmann{at} (D.M.K.); a.lieb{at} (A.L.)
  • * These authors contributed equally to this work.

  • Present address: Department of Experimental Neurology, Charité—Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.

  • Present address: Department of Pharmacology, UCL School of Pharmacy, University College London, London, UK.


Article usage

Article usage: April 2019 to November 2019

Apr 20191992683396
May 201940519132
Jun 20192126655
Jul 20192519569
Aug 20191316554
Sep 20191215525
Oct 20191626360
Nov 201937715

Navigate This Article